CoChat

Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit

Memarzadeh, Farnaz, Varma, Rohit, Lin, Le-Tien, Parikh, Jignesh G., Dustin, Laurie, Alcaraz, Ana, Eliott, Dean · 2009 · Investigative Opthalmology & Visual Science

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

PURPOSE: To evaluate the efficacy of bevacizumab as an antifibrotic agent after trabeculectomy in rabbits. METHODS: Forty-two rabbits underwent trabeculectomy and were randomly assigned to receive a postoperative course of seven subconjunctival injections of bevacizumab (1.25 mg, 25 mg/mL), 5-fluorouracil (5-FU; 5 mg, 50 mg/mL), or balanced salt solution (BSS; 0.1 mL, control). Bleb survival and characteristics were evaluated over a 30-day period. The animals were killed on postoperative day (PD)10, PD20, and PD30. Histology and immunohistochemistry of the surgical eyes was performed to evaluate and grade the amount of scarring and fibrosis in each group. RESULTS: Bevacizumab significantly improved the outcome of filtration surgery in this model. Bevacizumab prolonged bleb survival compared with the 5-FU and control groups (16.0 +/- 1.3 days vs. 6.9 +/- 0.6 and 7.4 +/- 0.85 days, respectively; P < 0.001). Bevacizumab-treated eyes had significantly larger and higher blebs than the control and 5-FU-treated groups (P < 0.05). Histologic analysis revealed that eyes treated with bevacizumab had significantly less postoperative scarring at the microscopic level at PD10 and PD20 (P = 0.009). CONCLUSIONS: Postoperative subconjunctival injection of bevacizumab is associated with improved trabeculectomy bleb survival in the rabbit model. Bevacizumab may be a useful agent for improving success and limiting scar tissue formation after trabeculectomy.

Overview

Integrity signals

Registry

Crossref · 10.1167/iovs.08-2441

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

Items 101–120 of 120

Metadata

Authors
Memarzadeh, F., Varma, R., Lin, L.-T., Parikh, J. G., Dustin, L., Alcaraz, A., & Eliott, D.
Affiliations
  • Doheny Eye Institute (US)
  • University of Southern California (US)
  • Armed Forces Sung Shan General Hospital, Taipei, Taiwan, Republic of China; and
  • Western University of Health Sciences (US)
Venue
Investigative Opthalmology & Visual Science
Published
2009-07-01
Volume
50
Issue
7
Pages
3233
ISSN
  • 0146-0404 (ISSN-L)
  • 1552-5783
OpenAlex
W2154459059
Cited by
117
References
23
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 8 · 2018: 8 · 2017: 4 · 2016: 7 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 11
FWCI
10.50
Type
journal article
Language
en
Open access
closed
Locations
  • Investigative Ophthalmology & Visual Science (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Corneal surgery and disorders
  • Health Sciences › Medicine › Ophthalmology › Intraocular Surgery and Lenses
Keywords
bevacizumab, trabeculectomy, glaucoma filtration surgery, bleb survival, postoperative scarring, antifibrotic therapy, 5-fluorouracil, subconjunctival injection, bleb fibrosis, rabbit model
MeSH terms
Bevacizumab, Animals, Antibodies, Monoclonal, Antimetabolites, Antineoplastic, Conjunctiva, Disease Models, Animal, Fibroblasts, Fibrosis, Fluorouracil, Glaucoma, Injections, Intraocular Pressure, Postoperative Care, Prognosis, Rabbits, Sclera, Trabeculectomy, Wound Healing, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.